Peer-reviewed research demonstrates dramatic improvement in identifying and closing quality gaps for Medicaid patients, outperforming current methods by 35 percentage points
Read More
CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitope
Phase 1 study in adults with active and chronic active renal allograft AMR planned to initiate
AMR is a leading cause of kidney transplant loss, leading to dialysis and/or repeat renal transplant
-Company closes approximately $5.47 million in equity financing in 2Q/3Q25
-TH104 potentially fills a critical National Security Need against Weaponized Fentanyl
-TH023 may fulfill the promise of delivering a safe and effective oral antibody medication against inflammation
-Company Strengthens Operational Leadership, Corporate Governance and Accounting
From Dr. Lyle Craker, University of Mass. to Duane Boise, CEO of MMJ BioPharma Cultivation;
Dr. Craker died still waiting for the DEA to embrace cannabis science. The same cannot be allowed to happen to MMJ BioPharma Cultivation, whose FDA Multiple Sclerosis and Huntington's Disease clinical trials could bring relief to patients suffering from incurable neurological disorders.
Read More
With the confirmation of incoming DEA Administrator Terrance Cole, the opportunity for reform has arrived. The DEA must choose between outdated drug war politics and advancing public health.
MMJ International Holdings Issues Clarification on Irvine Labs.
Read MoreReports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13)
Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end, primarily driven by timing of deliveries for contracted revenue into the first quarter of 2026
Improves 2025 expected GAAP operating expenses by approximately $400 million to a range of $5.9 to $6.1 billion
Reiterates 2025 expected year-end cash balance of approximately $6 billion
Announced three recent U.S. FDA approvals and positive Phase 3 efficacy results for seasonal influenza vaccine
Read More
Newly confirmed DEA Administrator Terrance Cole faces a defining choice: Will he break ranks with the agency's deeply entrenched anti-cannabis cabal-or will he become just another DEA figurehead parroting the same tired "gateway drug" propaganda while Americans suffer, science stalls, and corruption thrives?
The public, the scientific community, and thousands of patients are watching-and the window for Cole to make a meaningful impact is rapidly closing.
Read More
Professional & Friendly:
Now accepting new patients with short wait times and personalized care near Maple Shade and Riverton
Community-Oriented:
Local dental office steps up to serve patients after recent practice closures in the area
Value-Focused:
Gentle, affordable, and timely dental care available just minutes from Maple Shade and Riverton
Read More
As the sports memorabilia world confronts fraud and chaos, Infinite Auctions (OTC Pink:MDCE) delivers ironclad provenance and authenticity-led by the $242,400 sale of a LeBron James Miami Heat NBA Finals jersey sourced directly from Upper Deck and LeBron James.
Read More
With the opening of a new clinic, The Longevity Centers of America is expanding its signature blend of natural healing and modern wellness therapies into the greater Greenville region.
Read More
First sublingual pre-workout single-serving supplement that delivers 50mg of caffeine rapidly to the body, is now available to order via Aspire's new direct-to-consumer shopping experience
~ Productive FDA Meeting Highlights Path Toward Overdose Protection Labeling and 505(b)(2) Regulatory Strategy ~
~ FDA and Ensysce Aligned on Collaborative Approach to Ensure Product's Full Safety Benefits are Recognized ~
Read More
Pressured by Cost, Aging Systems, and Workflow Misalignment, Under-50-Bed Hospitals Indicate an Acceleration Toward Next-Generation EHR Transitions
Read More
Black Book Report Highlights Total Cost of Ownership and Cybersecurity Threats as Primary Factors Influencing Shift Toward Affordable, Cloud-Based EHR Solutions
Read More
Ariessence Pure PDGF+ is now available at Rubinstein Plastic Surgery Center, offering topical and injectable applications to support post-procedure healing, early skin aging, and hair restoration.
Read MoreTopical Ketamir-2 significantly reduced both acute and inflammatory pain behaviors in animals, demonstrating rapid onset, durable effect, and comparable efficacy to injected morphine across both pain phases
Read More
Terrance Cole's First Test as Administrator
MMJ BioPharma Cultivation's case exposes DEA's Diversion Control Division as a cartel of obstructionists who have abandoned science, betrayed public trust, and refused to follow the law.
New DEA Administrator Terrance Cole inherited a mess. But now he has a chance to do something Judge Mulrooney, Thomas Prevoznik, Matthew Straitand Aarathi Haig never would: Tell the truth. Follow the law. And approve MMJ's long-blocked registration so clinical trials can finally begin.
Read More
Sia/LBG has been awarded a supplemental grant by the Gates Foundation to enhance its web-based cost and environmental impact modeling resource for pharmaceutical APIs Cost of Goods (COGs).
Read More
This year's ride will raise critical funds to support the NCCS' Beyond the Cure Ambassador Scholarship Program, which empowers childhood cancer survivors to achieve their academic and professional dreams.
Read More
Using eXoZymes' AI-driven exozymes platform, NCTx has demonstrated lab scale validation with 4 grams of NCT produced at a 96% yield and with a purity higher than 99%.
NCT project went from concept to gram scale production in 5 months and at a fraction of normal SynBio R&D cost.
N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity.
Early access partners under material transfer agreement can sample the product and eXoZymes and NCTx is actively looking to increase the number of partners.
Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion as the Company prepares to launch U.S. Phase 2a by year-end
Read MoreU.S. CBD market projected to exceed $36 billion by 2032 as foot traffic rebounds in top-tier malls with over 122 million monthly U.S. shoppers - CBDL strategically positioned at the intersection of both trends
Read More
DEA Counsel's Conduct: Is It Fraud on the Tribunal?
DEA attorney Aarathi D. Haig submitted a formal legal response on July 25, 2025 to DEA Administrator Terry Cole, asserting that MMJ BioPharma Cultivation lacked a bona fide supply agreement (BFSA) - the critical requirement for Schedule I bulk manufacturing registration.
But this is provably false. That misrepresentation - made knowingly and in writing to the DEA Administrator and under the guise of the law - raises serious civil and criminal red flags.
Read More
Biolog, a leading provider of microbial identification and phenotypic characterization tools and services, announced today that both its anaerobic media and anaerobic chambers have received CE marking, clearing the way for broader international use
Read More
Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is safe and well-tolerated in healthy elderly volunteers, showing a favourable pharmacokinetic profile and high brain penetration. These findings support the advancement of SUL-238 into further clinical development for Alzheimer's and other neurodegenerative diseases.
Read More